Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Autophagy inducer rapamycin treatment reduces IFN-I–mediated Inflammation and improves anti–HIV-1 T cell response in vivo
Wenli Mu, … , Scott G. Kitchen, Anjie Zhen
Wenli Mu, … , Scott G. Kitchen, Anjie Zhen
Published November 22, 2022
Citation Information: JCI Insight. 2022;7(22):e159136. https://doi.org/10.1172/jci.insight.159136.
View: Text | PDF
Research Article AIDS/HIV Inflammation

Autophagy inducer rapamycin treatment reduces IFN-I–mediated Inflammation and improves anti–HIV-1 T cell response in vivo

  • Text
  • PDF
Abstract

A hallmark of HIV-1 infection is chronic inflammation, even in patients treated with antiretroviral therapy (ART). Chronic inflammation drives HIV-1 pathogenesis, leading to loss of CD4+ T cells and exhaustion of antiviral immunity. Therefore, strategies to safely reduce systematic inflammation are needed to halt disease progression and restore defective immune responses. Autophagy is a cellular mechanism for disposal of damaged organelles and elimination of intracellular pathogens. Autophagy is pivotal for energy homeostasis and plays critical roles in regulating immunity. However, how it regulates inflammation and antiviral T cell responses during HIV infection is unclear. Here, we demonstrate that autophagy is directly linked to IFN-I signaling, which is a key driver of immune activation and T cell exhaustion during chronic HIV infection. Impairment of autophagy leads to spontaneous IFN-I signaling, and autophagy induction reduces IFN-I signaling in monocytic cells. Importantly, in HIV-1–infected humanized mice, autophagy inducer rapamycin treatment significantly reduced persistent IFN-I–mediated inflammation and improved antiviral T cell responses. Cotreatment of rapamycin with ART led to significantly reduced viral rebound after ART withdrawal. Taken together, our data suggest that therapeutically targeting autophagy is a promising approach to treat persistent inflammation and improve immune control of HIV replication.

Authors

Wenli Mu, Valerie Rezek, Heather Martin, Mayra A. Carrillo, Shallu Tomer, Philip Hamid, Miguel A. Lizarraga, Tristan D. Tibbe, Otto O. Yang, Beth D. Jamieson, Scott G. Kitchen, Anjie Zhen

×

Figure 3

Combination of ART and autophagy inducer rapamycin (Rapa) treatment effectively decreases inflammation, ISG expression, and viral replication in HIV-infected humanized BLT mice.

Options: View larger image (or click on image) Download as PowerPoint
Combination of ART and autophagy inducer rapamycin (Rapa) treatment effe...
(A) Eight weeks after immune reconstitution, BLT humanized mice were infected with HIVNFNSXL9 for 8 weeks. Afterward, mice were treated with ART and rapamycin or DMSO control for 4 weeks before necropsy. (B) PD-1, TIM-3, CD38, and HLA-DR expression was measured by flow cytometry (quantitatively by gating of percentages positive ± SEM) on peripheral blood CD8+ T cells from rapamycin or control mice (n = 6–7 per group). (C) Autophagy flux was detected by Western blotting of LC3-I, LC-II, ATG5, and actin using pooled splenocytes from DMSO or rapamycin-treated groups at necropsy (n = 5 per group). The ratio of LC3-II/actin was calculated by ImageJ. (D) Expression levels of human ISGs MX1, OAS1, and IRF7 in multiple lymphoid tissues from humanized BLT mice after treatment were measured by real-time PCR (n = 6–7 per group). (E) Splenocytes from HIV-1–infected mice treated with ART and rapamycin or DMSO were isolated and stained with intracellular Abs against human IRF7 and MX1. MFIs of the ISGs IRF7 and MX1 on human monocytes were measured by flow cytometry (n = 5–7 per group). (F) Relative HIV cellular RNA/HPRT1 expression from multiple lymphoid tissues after the indicated treatment, as compared with control blood. (n = 5–7 per group). Each dot represents an individual mouse; horizontal bars indicate median values. *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney U test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts